Rubius Therapeutics (RUBY) Sees Unusually-High Trading Volume
Shares of Rubius Therapeutics Inc (NASDAQ:RUBY) saw unusually-strong trading volume on Friday . Approximately 2,834,366 shares changed hands during trading, an increase of 825% from the previous session’s volume of 306,401 shares.The stock last traded at $16.29 and had previously closed at $15.58.
A number of research analysts recently issued reports on the company. Morgan Stanley cut their price target on Rubius Therapeutics from $37.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, December 19th. ValuEngine cut Rubius Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, Zacks Investment Research raised Rubius Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Wednesday, January 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $30.00.
The company has a debt-to-equity ratio of 0.06, a current ratio of 25.78 and a quick ratio of 25.78.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/rubius-therapeutics-ruby-sees-unusually-high-trading-volume/2897190.html.
About Rubius Therapeutics (NASDAQ:RUBY)
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
See Also: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.